ICIs Improve pCR Rates in Early ER+/HER2– Breast Cancer
Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor–positive, HER2-negative breast cancer.